Large Investor Urges Celera to Renegotiate Sale to Quest

Activist hedge fund business Starboard Value & Opportunity Fund said the $671 million proposed deal fails to factor in a royalty interest to Celera related to technology licensed to Merck to develop an osteoporosis drug.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories